Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials
- Resource Type
- article
- Authors
- Heinz Gisslinger
- Source
- Turkish Journal of Hematology, Vol 40, Iss 4, Pp 266-268 (2023)
- Subject
- ph-negative chronic myeloproliferative neoplasm
chronic myeloproliferative neoplasms
neoplasia
hematopoietic stem and progenitor cells
hematopoiesis
pharmacotherapeutics
oncogenes
Diseases of the blood and blood-forming organs
RC633-647.5
- Language
- English
- ISSN
- 1308-5263
Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life, the slowing of disease progression, and long event-free survival. Data support the use of RopegIFN in both early PV therapy and second-line and beyond.